GSK’s External Alliances Evolve With Galapagos Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal between GSK’s Center of Excellence for External Drug Discovery and Galapagos will focus on osteoarthritis treatments.
You may also be interested in...
Blocking Cathepsin K: Merck Wins Where Novartis Lost
Better specificity gives bone drug odanacatib success in Phase IIb.
Blocking Cathepsin K: Merck Wins Where Novartis Lost
Better specificity gives bone drug odanacatib success in Phase IIb.
GSK Links With OncoMed, Galapagos To Boost Oncologic, Anti-Infective Pipelines
Deals present possible $1.4 billion for OncoMed, €245 million for Galapagos through GSK’s external drug discovery centers.